AVAC's Good Participatory Practice Initiative
Good Participatory Practice Guidelines for
Biomedical HIV Prevention Trials (GPP) are
designed to provide systematic guidance on the
roles and responsibilities of trial sponsors
and trial implementers towards participants and
their communities.
AVAC, through its GPP initiative, aims to have a significant effect on the ethical implementation of clinical trials in biomedical HIV prevention research globally by:
Community Consultations on the GPP guidelines
Although the GPP guidelines were published in November 2007, AVAC felt it was important to generate broader stakeholder feedback to identify the opportunities, obstacles, and additional needs of organizations, including community groups, interested in using this new tool. In June 2008, AVAC issued a series of small grants to biomedical HIV prevention stakeholders, including community groups, trial sites, and NGOs.
Through consultative meetings, interviews, focus group discussions, and other activities, AVAC's GPP Partners engaged with stakeholder groups to pilot and gain critical feedback on the GPP guidelines. Project activities are now completed, and results from the consultations will be published by the end of 2009.
AVAC's GPP Partners:
To see a global map of AVAC's GPP partners, click here.
View our poster presented at AIDS Vaccine 2009 about the GPP partner consultations
Investigating the utility and relevance of the good participatory practice guidelines for biomedical HIV prevention trials.
GPP Baseline Survey
As a part of AVAC's aim to monitor and evaluate implementation of the GPP guidelines, a baseline survey was created for stakeholders of biomedical HIV prevention research, including trial sponsors and networks, trial site staff, community members, and regulators.
The purpose of the survey was to gauge biomedical HIV prevention stakeholder awareness and utilization of the GPP guidelines, assess attitudes around community engagement in biomedical HIV prevention trials, and to identify gaps in achieving appropriate community engagement. The survey was launched in early 2009, and results will be released in late 2009.
View our poster presented at AIDS Vaccine 2009, Paris, about they survey.
Good Participatory Practice (GPP) Guidelines Begin to Take Root.
AVAC, through its GPP initiative, aims to have a significant effect on the ethical implementation of clinical trials in biomedical HIV prevention research globally by:
- Raising awareness about and disseminating the Good Participatory Practice guidelines
- Advocating that the guidelines and their minimum elements be adopted by key stakeholders and implemented at trial sites
- Providing materials, resources, and technical assistance to stakeholders to improve their understanding and ability to use and implement the guidelines
- Monitoring and evaluating the implementation of the GPP guidelines globally
- Fostering relationships with stakeholders who are using or would like to use the guidelines
- Conducting periodic reviews and revisions of the GPP Guidelines
Community Consultations on the GPP guidelines
Although the GPP guidelines were published in November 2007, AVAC felt it was important to generate broader stakeholder feedback to identify the opportunities, obstacles, and additional needs of organizations, including community groups, interested in using this new tool. In June 2008, AVAC issued a series of small grants to biomedical HIV prevention stakeholders, including community groups, trial sites, and NGOs.
Through consultative meetings, interviews, focus group discussions, and other activities, AVAC's GPP Partners engaged with stakeholder groups to pilot and gain critical feedback on the GPP guidelines. Project activities are now completed, and results from the consultations will be published by the end of 2009.
AVAC's GPP Partners:
- Asociacion Civil Selva Amazonica, Peru
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
- Community Education Group, Inc. (CEG), United States
- Grupo de Incentivo a Vida (GIV) with Unidade de Pesquisa de Vacina Anti-HIV (UPSP), Brazil
- Kenya AIDS NGOs Consortium (KANCO) with Kenya AIDS Vaccine Initiative (KAVI) University of Nairobi Centre for HIV Prevention & Research (UoN-CHIVPR), Kenya
- Makerere University - Walter Reed Project (MUWRP), Uganda
- National AIDS Education & Services for Minorities, Inc. (NAESM), United States
- New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), Nigeria
- Perinatal HIV Research Unit (PHRU), South Africa
- Planeta Salud, Spain
- Sex Workers Project at the Urban Justice Center, United States
- Thai AIDS Treatment Action Group (TTAG), Thailand
To see a global map of AVAC's GPP partners, click here.
View our poster presented at AIDS Vaccine 2009 about the GPP partner consultations
Investigating the utility and relevance of the good participatory practice guidelines for biomedical HIV prevention trials.
GPP Baseline Survey
As a part of AVAC's aim to monitor and evaluate implementation of the GPP guidelines, a baseline survey was created for stakeholders of biomedical HIV prevention research, including trial sponsors and networks, trial site staff, community members, and regulators.
The purpose of the survey was to gauge biomedical HIV prevention stakeholder awareness and utilization of the GPP guidelines, assess attitudes around community engagement in biomedical HIV prevention trials, and to identify gaps in achieving appropriate community engagement. The survey was launched in early 2009, and results will be released in late 2009.
View our poster presented at AIDS Vaccine 2009, Paris, about they survey.
Good Participatory Practice (GPP) Guidelines Begin to Take Root.